ebdarokimab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
ebdarokimab

GtoPdb Ligand ID: 13875

Synonyms: AK-101 | AK101

ebdarokimab is an approved drug

Compound class: Antibody

Comment: Ebdarokimab (AK101) is a humanized IgG1-κ, dual IL-12/IL-23 targeting monoclonal antibody. It binds to the common p40 subunit (IL12B) of these cytokines and disrupts pro-inflammatory signalling via their receptors on T cells and natural killer (NK) cells.

Summary
Biological activity
Clinical data
Immunopharmacology

Immunopharmacology Comments
Targets dysregulated immune responses by neutralising the pro-inflammatory cytokines IL-12 and IL-23 which drive chronic pathology in autoimmune conditions. Blocking IL-12 activity reduces activation and proliferation of Th1 cells and their production of IFNγ and TNFα. Blocking IL-23 activity reduces differentiation of Th17 cells and IL-17 release.

Immunopharmacology Comments

Targets dysregulated immune responses by neutralising the pro-inflammatory cytokines IL-12 and IL-23 which drive chronic pathology in autoimmune conditions. Blocking IL-12 activity reduces activation and proliferation of Th1 cells and their production of IFNγ and TNFα. Blocking IL-23 activity reduces differentiation of Th17 cells and IL-17 release.